The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFusion Antibody Regulatory News (FAB)

Share Price Information for Fusion Antibody (FAB)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3.40
Bid: 3.30
Ask: 3.50
Change: 0.00 (0.00%)
Spread: 0.20 (6.061%)
Open: 3.40
High: 3.40
Low: 3.40
Prev. Close: 3.40
FAB Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Site Update

11 Nov 2008 07:00

RNS Number : 8653H
Fabian Romania Limited
11 November 2008
 

Fabian Romania Limited ("Fabian Romania" or the "Company")

Fabian Romania achieves Building Permit for "The Orchard" residential development site in Timisoara.

Fabian Romania along with its development partner Coltex Construct has been granted the building permit for its residential development scheme of 429 apartments in Timisoara.

The Orchard will provide 429 high quality apartments constructed in two phases, totalling 38,812 sqm with an additional 540 car spaces. 

Designed by international architects, Jestico Whiles, the Directors of Fabian Romania believe that it will provide a new degree of quality residential product not seen before in the local market. The site is located 10 minutes to the north west of Timisoara city centre in a residential neighbourhood with good access just off Strada Textilistolor, one of the main routes travelling north out of the city. 

Timisoara is built on the site of an historical Roman fortress. Over the years it has been influenced by many cultures and is now an important university city with strong links to its industrial heritage. The population has expanded rapidly over the last 10 years to over 300,000. International companies have invested in the city including Continental, Nestle and Procter & Gamble. As the wealth of the city has grown this has created demand for residential development.

Commenting on the transaction, Mark Owen, Property Director of Fabian Capital, the Company's Investment Manager said: 

"This has been a phased land acquisition and we are pleased to have achieved all the permits necessary to start construction. The scheme is an excellent design and well located just north of the city and close to existing retail shopping malls. In light of current market conditions we have secured the value of the site by obtaining these permits and will assess market conditions early next year and establish when the time is right for construction to commence."

Enquiries

 

Fabian Capital:

Anthony Foster +44 20 7499 9988

 

Deloitte Corporate Finance - Nominated Adviser to Fabian Romania

 

Mike Bell +44 20 7007 1463

 

Shore Capital Stockbrokers Limited - Joint Broker to Fabian Romania

 

Dru Danford +44 20 7408 2090

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCEAXFEFLFPFFE
Date   Source Headline
2nd May 20247:00 amRNSInvestor presentation
30th Apr 20247:00 amRNSYear-end trading statement
16th Apr 20247:00 amRNSChange of auditor
15th Apr 20247:00 amRNSContract to develop a bespoke OptiPhage library
2nd Apr 20242:34 pmRNSBlock admission six monthly return
28th Mar 20245:00 pmRNSTotal Voting Rights
11th Mar 20243:04 pmRNSHolding(s) in Company
11th Mar 20249:10 amRNSHolding(s) in Company
8th Mar 20243:09 pmRNSHolding(s) in Company
5th Mar 202410:40 amRNSResult of General Meeting and Total Voting Rights
29th Feb 20245:00 pmRNSTotal Voting Rights
27th Feb 20247:00 amRNSFirst purchase order under MSA
14th Feb 20247:15 amRNSGrant of options and issue of shares to directors
14th Feb 20247:00 amRNSPlacing to raise £1,375,000
6th Feb 20247:00 amRNSFollow-on project award and R&D update
1st Feb 20247:00 amRNSHMRC R&D tax credit
4th Dec 202312:26 pmRNSDirector/PDMR Shareholding
4th Dec 20237:00 amRNSHalf-year Report
28th Nov 20237:00 amRNSOptiMAL collaboration agreement
9th Nov 20237:00 amRNSHalf year trading update
27th Oct 202311:57 amRNSResult of AGM
4th Oct 20232:45 pmRNSBlock admission six monthly return
29th Sep 20237:00 amRNSFinal Results
29th Aug 20237:00 amRNSUpdate on AI/ML-Ab service offering
24th Aug 20237:00 amRNSAppointment of interim CFO
21st Aug 20237:00 amRNSUpdate on AI/ML-Ab™ antibody discovery service
14th Aug 20237:00 amRNSUpdate on restructure and cost savings
30th Jun 20235:00 pmRNSTotal Voting Rights
16th Jun 202310:09 amRNSHolding(s) in Company
15th Jun 20239:45 amRNSHolding(s) in Company
13th Jun 20232:44 pmRNSHolding(s) in Company
12th Jun 20233:34 pmRNSHolding(s) in Company
12th Jun 202311:02 amRNSDirector/PDMR Shareholding
8th Jun 202310:39 amRNSResult of GM and total voting rights
31st May 20235:00 pmRNSTotal Voting Rights
26th May 20234:57 pmRNSHolding(s) in Company
26th May 20231:33 pmRNSHolding(s) in Company
23rd May 20237:00 amRNSResult of Retail Offer and Notice of GM
19th May 202310:01 amRNSREX Retail Offer
19th May 202310:00 amRNSPlacing, Subscription and Retail Offer
3rd Apr 20237:00 amRNSBlock listing Interim Review
31st Mar 20237:00 amRNSChange of Registered Office
21st Mar 20237:00 amRNSPatent application
6th Mar 202311:05 amRNSSecond Price Monitoring Extn
6th Mar 202311:00 amRNSPrice Monitoring Extension
6th Mar 20237:00 amRNSTrading Statement
9th Feb 20237:00 amRNSR&D update: Mammalian Display service
9th Jan 20234:40 pmRNSSecond Price Monitoring Extn
9th Jan 20234:35 pmRNSPrice Monitoring Extension
9th Jan 20232:05 pmRNSSecond Price Monitoring Extn

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.